CL2007002879A1 - Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer. - Google Patents

Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer.

Info

Publication number
CL2007002879A1
CL2007002879A1 CL200702879A CL2007002879A CL2007002879A1 CL 2007002879 A1 CL2007002879 A1 CL 2007002879A1 CL 200702879 A CL200702879 A CL 200702879A CL 2007002879 A CL2007002879 A CL 2007002879A CL 2007002879 A1 CL2007002879 A1 CL 2007002879A1
Authority
CL
Chile
Prior art keywords
nectina
understands
produces
pharmaceutical composition
monoclonal antibody
Prior art date
Application number
CL200702879A
Other languages
English (en)
Inventor
Sato Tsutomu Oshima Tomo Shuji
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44083820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002879(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ARP070101453A external-priority patent/AR060362A1/es
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2007002879A1 publication Critical patent/CL2007002879A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL200702879A 2007-04-04 2007-10-05 Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer. CL2007002879A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP070101453A AR060362A1 (es) 2005-10-07 2007-04-04 Agente para prevenir / tratar el cancer
JP2007100876 2007-04-06

Publications (1)

Publication Number Publication Date
CL2007002879A1 true CL2007002879A1 (es) 2008-06-27

Family

ID=44083820

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702879A CL2007002879A1 (es) 2007-04-04 2007-10-05 Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer.

Country Status (21)

Country Link
US (1) US20100008928A1 (es)
EP (1) EP2067791A4 (es)
JP (1) JPWO2008044754A1 (es)
KR (1) KR20090078339A (es)
CN (1) CN101541834A (es)
AR (1) AR063153A1 (es)
AU (1) AU2007307536A1 (es)
BR (1) BRPI0717024A2 (es)
CA (1) CA2666249A1 (es)
CL (1) CL2007002879A1 (es)
CO (1) CO6190538A2 (es)
EC (1) ECSP099276A (es)
IL (1) IL197389A0 (es)
MA (1) MA30816B1 (es)
MX (1) MX2009003126A (es)
NO (1) NO20091783L (es)
PE (1) PE20081456A1 (es)
RU (1) RU2009117237A (es)
TN (1) TN2009000090A1 (es)
TW (1) TW200823235A (es)
WO (1) WO2008044754A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012092374A2 (en) * 2010-12-31 2012-07-05 Short Jay M Express humanization of antibodies
ES2672695T3 (es) * 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
MX2014014951A (es) * 2012-06-06 2015-03-13 Oncomed Pharm Inc Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
WO2014069681A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2014069682A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
IL254039B2 (en) * 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
MX2019006072A (es) 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
JP7348072B2 (ja) 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
JP7072715B2 (ja) 2018-07-20 2022-05-20 サーフィス オンコロジー インコーポレイテッド 抗ｃｄ１１２ｒ組成物及び方法
EP3908372A1 (en) * 2019-01-13 2021-11-17 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human nectin-2
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
EP4277904A1 (en) 2021-01-15 2023-11-22 Seagen Inc. Immunomodulatory antibody-drug conjugates
MX2023009113A (es) 2021-02-03 2023-08-10 Seagen Inc Conjugados y compuestos inmunoestimulantes.
CN117751139A (zh) * 2021-03-31 2024-03-22 涌现制药股份公司 抗Nectin-4抗体依喜替康缀合物
CA3243763A1 (en) 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies directed against nectin-2 and their drug conjugates
EP4518905A1 (en) 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
IL318450A (en) 2022-08-03 2025-03-01 Seagen Inc Immunostimulatory ANTI-PD-L1-Drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
CN119096936A (zh) * 2024-08-28 2024-12-10 南方医科大学第三附属医院（广东省骨科研究院） 一种胆管癌足垫腘窝淋巴结自发转移动物模型的构建方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
AU4228699A (en) 1998-06-03 1999-12-20 Northwestern University Cellular proteins which mediate herpesvirus entry
US20030129685A1 (en) * 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
DE19852800C1 (de) 1998-11-16 2000-04-13 Univ Albert Ludwigs Freiburg Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist
US20030022279A1 (en) * 1999-06-14 2003-01-30 Fraser Christopher C. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU1305302A (en) 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
EP1402058A4 (en) 2001-06-05 2006-02-01 Exelixis Inc DGKS AS P53 PATH MODIFICATORS AND METHOD OF USE
CA2449303C (en) 2001-06-06 2014-10-14 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
WO2003020743A1 (en) 2001-09-05 2003-03-13 Regeneron Pharmaceuticals, Inc. Methods of expressing transgenes
US20030228319A1 (en) * 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005097204A1 (ja) 2004-04-09 2005-10-20 Takeda Pharmaceutical Company Limited 癌の予防・治療剤

Also Published As

Publication number Publication date
RU2009117237A (ru) 2010-11-20
MX2009003126A (es) 2009-04-06
CN101541834A (zh) 2009-09-23
WO2008044754A1 (en) 2008-04-17
EP2067791A4 (en) 2009-11-25
PE20081456A1 (es) 2008-11-27
MA30816B1 (fr) 2009-10-01
IL197389A0 (en) 2011-08-01
TN2009000090A1 (en) 2010-08-19
CO6190538A2 (es) 2010-08-19
AU2007307536A1 (en) 2008-04-17
CA2666249A1 (en) 2008-04-17
AR063153A1 (es) 2008-12-30
NO20091783L (no) 2009-07-01
JPWO2008044754A1 (ja) 2010-02-18
AU2007307536A2 (en) 2009-04-30
BRPI0717024A2 (pt) 2014-03-11
EP2067791A1 (en) 2009-06-10
KR20090078339A (ko) 2009-07-17
ECSP099276A (es) 2009-06-30
TW200823235A (en) 2008-06-01
US20100008928A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CL2007003794A1 (es) Anticuerpo anti-receptor del factor de crecimiento insulinico i (igf-ir); polinucleotido que lo codifica; metodo de produccion; composicion que lo comprende; y su uso para tratar cancer.
CL2008001334A1 (es) Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003212A1 (es) Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2008000029A1 (es) Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2011000711A1 (es) Anticuerpo monoclonal que se une al receptor de regulacion negativa (nrr) de notch2; formulacion farmaceutica que lo comprende; y su uso para tratar una enfermedad maligna por celula b o melanoma.
BRPI0811907A2 (pt) Anticorpos monoclonais contra claudina-18 para tratamento de câncer.
HN2009000379A (es) Anticuerpo especifico prlr y sus usos
CL2008000754A1 (es) Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos.
CL2007000478A1 (es) Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t
CL2015000028A1 (es) Inmunoconjugado que comprende un anticuerpo anti-cd79b unido a un agente citotóxico derivado de nemorrubicina; formulación farmacéutica que lo comprende; y uso para tratar cáncer cd79b positivo.
BRPI0812005A2 (pt) anticorpos humanizados para o globulômeros de ab(20-42) e seus usos.
IL197928A (en) A monoclonal antibody munched on steap-1, its immunoconjugates its uses
CL2008000197A1 (es) Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
HUE036477T2 (hu) Monoklonális anti-GT468 antitestek rák kezeléséhez
CL2008000793A1 (es) Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
CL2014000590A1 (es) Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.
BRPI0814420A2 (pt) composição, e, uso de álcool alcoxilado.
CL2008000794A1 (es) Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BR112013013781A2 (pt) anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer